Cargando…
Glycogenic Hepatopathy: Thinking Outside the Box
Glycogenic hepatopathy (GH) remains underrecognized in adults as most clinicians mistake it for the more common hepatic abnormality associated with uncontrolled diabetes mellitus in this age group, non-alcoholic fatty liver disease. This is also complicated by the fact that both entities are indisti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520193/ https://www.ncbi.nlm.nih.gov/pubmed/26269698 http://dx.doi.org/10.1159/000437048 |
_version_ | 1782383630342946816 |
---|---|
author | Parmar, Nishant Atiq, Muslim Austin, Lee Miller, Ross A. Smyrk, Thomas Ahmed, Kabir |
author_facet | Parmar, Nishant Atiq, Muslim Austin, Lee Miller, Ross A. Smyrk, Thomas Ahmed, Kabir |
author_sort | Parmar, Nishant |
collection | PubMed |
description | Glycogenic hepatopathy (GH) remains underrecognized in adults as most clinicians mistake it for the more common hepatic abnormality associated with uncontrolled diabetes mellitus in this age group, non-alcoholic fatty liver disease. This is also complicated by the fact that both entities are indistinguishable on liver ultrasound. We herein describe a similar predicament in which a young adult female presented with bilateral upper quadrant abdominal pain, tender hepatomegaly, lactic acidosis and a >10-fold increase in liver enzymes, which worsened after the administration of high-dose steroids. Despite intravenous normal saline resuscitation, serum transaminitis persisted in a fluctuating manner. Ultimately, a liver biopsy confirmed GH. Biochemically, GH is driven by high amounts of both circulating glucose and insulin or by the administration of high-dose steroids. Improving glycemic control is the mainstay of treatment for GH. However, in our case, improvement in glycated hemoglobin of just 0.6% was enough to achieve symptomatic relief, supporting recent claims of the involvement of other identified factors in disease development. |
format | Online Article Text |
id | pubmed-4520193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-45201932015-08-12 Glycogenic Hepatopathy: Thinking Outside the Box Parmar, Nishant Atiq, Muslim Austin, Lee Miller, Ross A. Smyrk, Thomas Ahmed, Kabir Case Rep Gastroenterol Published online: July, 2015 Glycogenic hepatopathy (GH) remains underrecognized in adults as most clinicians mistake it for the more common hepatic abnormality associated with uncontrolled diabetes mellitus in this age group, non-alcoholic fatty liver disease. This is also complicated by the fact that both entities are indistinguishable on liver ultrasound. We herein describe a similar predicament in which a young adult female presented with bilateral upper quadrant abdominal pain, tender hepatomegaly, lactic acidosis and a >10-fold increase in liver enzymes, which worsened after the administration of high-dose steroids. Despite intravenous normal saline resuscitation, serum transaminitis persisted in a fluctuating manner. Ultimately, a liver biopsy confirmed GH. Biochemically, GH is driven by high amounts of both circulating glucose and insulin or by the administration of high-dose steroids. Improving glycemic control is the mainstay of treatment for GH. However, in our case, improvement in glycated hemoglobin of just 0.6% was enough to achieve symptomatic relief, supporting recent claims of the involvement of other identified factors in disease development. S. Karger AG 2015-07-09 /pmc/articles/PMC4520193/ /pubmed/26269698 http://dx.doi.org/10.1159/000437048 Text en Copyright © 2015 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. |
spellingShingle | Published online: July, 2015 Parmar, Nishant Atiq, Muslim Austin, Lee Miller, Ross A. Smyrk, Thomas Ahmed, Kabir Glycogenic Hepatopathy: Thinking Outside the Box |
title | Glycogenic Hepatopathy: Thinking Outside the Box |
title_full | Glycogenic Hepatopathy: Thinking Outside the Box |
title_fullStr | Glycogenic Hepatopathy: Thinking Outside the Box |
title_full_unstemmed | Glycogenic Hepatopathy: Thinking Outside the Box |
title_short | Glycogenic Hepatopathy: Thinking Outside the Box |
title_sort | glycogenic hepatopathy: thinking outside the box |
topic | Published online: July, 2015 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520193/ https://www.ncbi.nlm.nih.gov/pubmed/26269698 http://dx.doi.org/10.1159/000437048 |
work_keys_str_mv | AT parmarnishant glycogenichepatopathythinkingoutsidethebox AT atiqmuslim glycogenichepatopathythinkingoutsidethebox AT austinlee glycogenichepatopathythinkingoutsidethebox AT millerrossa glycogenichepatopathythinkingoutsidethebox AT smyrkthomas glycogenichepatopathythinkingoutsidethebox AT ahmedkabir glycogenichepatopathythinkingoutsidethebox |